Medical Crossfire®: Key Strategies to Prioritize Testing and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care
Medical Crossfire®: Key Strategies to Prioritize Testing and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care is organized by Physicians' Education Resource, LLC (PER).
Release Date: May 15, 2023
Expiration Date: May 15, 2024
Description:
The use of molecular testing and biomarker-driven therapy has undergone marked growth and development for the management of non–small cell lung cancer (NSCLC) in recent years. As such, there is a critical need to provide education on how these tests work, emerging biomarkers (in particular, gene fusions), and the appropriate use of investigational therapies targeting current and emerging biomarkers to ultimately improve patients’ outcomes.
Medical Crossfire®, one of PER®’s signature educational formats, is a virtual program during which a panel of distinguished experts engages in spirited discussions and debates on a particular clinical topic. In this activity, 4 key thought leaders in pathology and medical oncology explore the latest data regarding current and emerging diagnostic and therapeutic strategies for patients with NSCLC that exhibits gene fusion.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Explain biomarker testing strategies including comprehensive genomic profiling, to detect rarer mutations and rearrangements in advanced non–small cell lung cancer (NSCLC) settings
• Determine approaches to practically integrate biomarker testing in community settings to identify oncogenic gene fusions among patients with NSCLC
Describe clinical trial evidence concerning the role of genotype-directed therapies in patients with NSCLC and oncogenic gene fusions
• Assess residual challenges and gaps that preclude optimized testing and treatment for oncogenic fusion-positive NSCLC, including strategies or ongoing trials intended to address these unmet needs in the field.